For how we live.
In the industry-funded evERA trial, giredestrant plus everolimus delayed progression of ER-positive breast cancer — but the clearest benefit was in ESR1-mutated tumours, and the endpoint was a surrogate, not survival.
A $12 million gift will test whether low-dose rapamycin changes the transition to frailty in adults over 65 — the first study of the drug designed around an outcome rather than a biomarker.
A 2025 review walked through every study of low-dose rapamycin in healthy adults. The immune findings are real, the outcome data do not exist, and the review's own worked example does not add up.